rhEPO联合蔗糖铁维持治疗胃肠道肿瘤化疗相关性贫血的临床观察  

Efficacy and safety of iron sucrose combined with rh EPO in treatment of chemotherapy-induced anemia in patients with gastrointestinal cancer

作　　者：曾冬香[1] 毕延智[1] 盛桂凤[1] 杨全良[1] 马剑[1] 

机构地区：[1]常州市第四人民医院肿瘤内科,江苏常州213001

出　　处：《实用肿瘤杂志》2015年第3期275-278,共4页Journal of Practical Oncology

摘　　要：目的观察重组人促红细胞生成素（recombinant human erythropoietin,rh EPO）注射液联合蔗糖铁治疗胃肠道肿瘤化疗相关性贫血的疗效和安全性。方法胃肠道肿瘤合并化疗相关性贫血的患者33例,予以rh EPO皮下注射（100~150 U/kg）,每周3次,至血红蛋白≥120 g/L停用或开始化疗时停用;同时补充蔗糖铁,每周2次,化疗期间继续应用,直至完成总补铁量。之后每2周以蔗糖铁100 mg维持。比较治疗前、后血红蛋白、红细胞比容、红细胞计数和生活质量的变化,并记录不良反应发生情况。结果与治疗前比较,33例患者经rh EPO及蔗糖铁治疗后,血红蛋白、红细胞计数、红细胞比容均有明显改善（P〈0.05）,有效率为81.8%;与治疗前比较,患者生活质量评分（Karnofsky评分）提高（P〈0.05）。治疗期间有1例患者出现低热,2例出现血压轻度升高。结论 rh EPO联合蔗糖铁维持治疗能明显提高胃肠道肿瘤患者的血红蛋白水平及治疗化疗相关性贫血,改善其生活质量,耐受性良好。Objective To evaluate the efficacy and safety of iron sucrose combined with recombinant human erythropoietin（ rh EPO） injection in the treatment of chemotherapy-induced anemia in patients with gastrointestinal cancer.Methods A total of 33 gastrointestinal cancer patients with chemotherapy-induced anemia received subcutaneous injection of rh EPO,100 ~ 150 U / kg,3 / week and oral administration of iron sucrose. The levels of hemoglobin（ Hb）,hematocrit（ HCT）,red blood cell count and Karnofsky Performance Scale（ KPS） were monitored before and after treatment. Adverse events were documented. Results The levels of Hb,HCT,RET and KPS were improved 4 weeks after treatment（ all P 0. 05） with a total effective rate of 81. 8%. During the treatment period,only fever and slight increase of blood pressure were observed in 3 cases. Conclusion The use of rh EPO with iron sucrose is safe and effective for chemotherapy-induced anemia in patients with gastrointestinal cancer.

关 键 词：胃肠肿瘤/药物疗法 胃肠肿瘤/并发症 红细胞生成素 重组/治疗应用 铁/治疗应用 蔗糖/治疗应用 贫血/药物疗法 贫血/病因学 注射 皮下 药物疗法 联合 随机对照试验 

分 类 号：R735[医药卫生—肿瘤] R730.53[医药卫生—临床医学]